OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Hematology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP	52
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon	51
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome	42
Hematological parameters and X-ray exposure among medical radiation workers: a systematic review and meta-analysis	34
Treating sickle cell disease in resource-limited sub-Saharan Africa: recent strategies and recommendations in addressing the gaps for the provision of evidence-based management	32
CD123-targeted therapy in acute myeloid leukemia	26
A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly	24
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis	24
Frequencies of glycosylphosphatidylinositol (GPI)-deficient cells using high-sensitivity flow cytometry as per the 2018 ICCS/ESCCA consensus guideline in patients with hematologic malignancy, aplastic	24
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia	23
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management	21
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care	21
Do we need more guidance on thrombophilia testing? Challenges and special considerations	21
The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas	20
What is the future of digital tools to help manage pain in sickle cell disease patients?	20
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma	19
Platelets: the point of interconnection among cancer, inflammation and cardiovascular diseases	18
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease	18
Correlation between hematocrit and the risk of common human cancers: results of a 1999–2020 observational survey and Mendelian randomization analysis	17
Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations	17
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective	16
Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors	15
Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations	15
Extended post-discharge thromboprophylaxis in hospitalized COVID-19 patients	14
Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management	14

BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia	13
The future of siRNA-mediated approaches to treat von Willebrand disease	13
Managing complications secondary to Waldenström’s macroglobulinemia	13
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B	13
Sickle cell disease and infertility risks: implications for counseling and care of affected girls and women	12
Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future	12
Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera	12
Efanesoctocog alfa for the prevention and treatment of bleeding in patients with hemophilia A	12
Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients	11
Impact of atrial fibrillation in onco-hematological patients in Europe: a targeted literature review	11
Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia	11
Bone marrow aspirate or biopsy for multiple myeloma: when percentages matter!	11
Voxelotor for the treatment of sickle cell disease in pediatric patients	11
Patient-centered care in von Willebrand disease: are we there yet?	11
BCL-2 inhibition in acute myeloid leukemia: resistance and combinations	11
Efficacy and safety of phosphatidylinositol 3-kinase inhibitors in patients with chronic lymphocytic leukemia: a meta-analysis and systematic review	11
An expert spotlight on inferior vena cava filters	10
A toolmaker’s perspective on CRISPR-directed gene editing as a therapeutic strategy for leukemia and beyond	10
Radiation therapy prior to CAR T-cell therapy in lymphoma: impact on patient outcomes	10
New directions to develop therapies for people with hemophilia	10
Development and internal validation of a prediction model for patients with hematologic diseases of fall risk: a cohort study	10
Thrombotic events in children and adolescent patients with SARS-CoV-2 infection: a systematic review with meta-analysis on incidence and management	10
Managing blood supplies during natural disasters, humanitarian emergencies, and pandemics: lessons learned from COVID-19	10
Emicizumab and unmet needs of patients with hemophilia a who are managed with replacement therapies	9
The National Hemophilia Foundation’s State of the Science Research Summit: the foundation of a national research blueprint for inherited bleeding disorders	9
Molecular targets for the treatment of AML in the forthcoming 5th World Health Organization Classification of Haematolymphoid Tumours	9
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding	9
Is next-generation sequencing the future of measurable residual disease assays for Philadelphia chromosome-positive acute lymphoblastic leukemia?	9
Immunodeficiency-associated Hodgkin lymphoma	9
Rivaroxaban plus aspirin after lower–extremity revascularization	8
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors	8
Bad players in AL amyloidosis in the current era of treatment	8
Optimizing long-term joint health in the treatment of hemophilia	8
Pegcetacoplan: the first and only C3-targeted therapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria	8
Is the occurrence of deep vein thrombosis related to the fracture site? A two-sample Mendelian randomization study	8
Oral decitabine in acute myeloid leukemia: assessing efficacy, safety, and future implications for older patients	8
Hematology in the post-COVID era: spotlight on vaccine-induced immune thrombotic thrombocytopenia and a conceptual framework (the 4P’s) for anti-PF4 diseases	8
What is the importance of monitoring iron levels in different organs over time with magnetic resonance imaging in transfusion-dependent thalassemia patients?	8
Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia	8
The impact of oral health promotion on the quality of life of children with bleeding disorders: fighting misconceptions	7
Sickle cell disease in gulf cooperation council countries: a systematic review	7
Novel mechanisms of action of emerging therapies of hereditary thrombotic thrombocytopenic purpura	7
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS	7
Lived experience experts: a name created by us for us	7
Hematological disorders in children with Down syndrome	7
Role of volumetric analyses on [¹⁸F]FDG PET/CT in pediatric Hodgkin lymphoma	7
Long-term follow-up of patients with hairy cell leukemia in the south of Iran	7
Problems faced by people with hemophilia aged 18–35 years in social life: a qualitative study	7
Monoclonal antibodies used for the management of hemataological disorders	7
Real-world treatment patterns and outcomes in people with von Willebrand disease treated prophylactically with recombinant von Willebrand factor in the United States	7

Bridging the gap: how do we enroll more racial-ethnic minority patients in hematological drug trials?	6
Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders	6
Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies	6
Advancements in targeting CD30 for lymphoma therapy: a historical perspective and future directions	6
Identifying prognostic gene panels in acute myeloid leukemia	6
Targeting von Willebrand disease: the current status and future directions of management therapies	6
Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms	6
Pomalidomide combined with dexamethasone for the treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis	6
An update on novel therapies for treating patients with arterial thrombosis	6
Trends of chronic lymphocytic leukemia incidence and mortality in the United States: a population-based study over the last four decades	6
Exploring health disparities in diagnosing multiple myeloma	6
Revisiting the prognostic role of FLT3 mutations in acute myelogenous leukemia	6
Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma	6
Navigating the gap between guidelines and practical challenges in selecting first-line therapy for chronic lymphocytic leukemia	6
Genetic variant of endothelial protein C receptor genes and its serum level in B thalassemic children	6
Novel BCR-ABL1 tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia	6
Advances in our understanding of genetic markers and targeted therapies for pediatric LCH	6
Circ_0035381 contributes to the progression of acute myeloid leukemia via regulating miR-186-5p/CDCA3 pathway	6
Curative effect of motherwort combined with ethinylestradiol-cyproterone acetate on dysfunctional uterine bleeding	6
Challenges in the diagnosis of thrombotic thrombocytopenic purpura	6
New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond	6
HIV-1 infection in sickle cell disease and sickle cell trait: role of iron and innate response	5
An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency	5
How clinicians and persons with hemophilia may approach shared decision-making	5
Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review	5
Characterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review	5
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemia	5
A systematic literature review of the epidemiology, quality of life, and economic burden, including disease pathways and treatment patterns of relapsed/refractory classical Hodgkin lymphoma	5
Exploring the genetic relationship between deep vein thrombosis and plasma protein: a new research idea	5
Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin	5
Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia	5
Modifiable lifestyle risk factors and survival after diagnosis with multiple myeloma	5
Kompetitive allele specific PCR (KASP) based genotyping of sickle gene in the selected sub-ethnic tribal population of Gujarat and Madhya Pradesh	5
Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes	5
Revolutionizing hypertension treatment: aprocitentan’s dual action against resistant hypertension	5
Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors	5
Avapritinib for Systemic Mastocytosis	5
Targeting CD123 in BPDCN: an emerging field	5
NSAIDS/COXIBS for the treatment of musculoskeletal pain secondary to hemophilic arthropathy	5
Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them	5